The FDA approved using the drug Nelarabine in treating patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. Nelarabine is slightly soluble to soluble in water. It melts with decomposition between 209°, and 217° C. Nelarabine is a pro-drug of the deoxyguanosine analogue 9-β-D-arabinofuranosyl guanine 266 (ara-G), a nucleoside metabolic inhibitor. Nelarabine is demethylated by adenosine deaminase 267 (ADA) to ara-G, mono-phosphorylated by deoxyguanosine kinase, and deoxycytidine kinase and 268 subsequently converted to the active 5’-triphosphate, ara-GTP. For intravenous infusion, the drug Nelarabine is supplied in 250 mg/50 mL (5 mg/mL). Nelarabine administration should be discontinued for neurologic adverse reactions of NCI Common Toxicity Criteria grade 2 or greater. Dosage may be delayed for other toxicities, including hematologic toxicity. The cost of Nelarabine is economical, and one can find this medication from any nearby licensed pharmaceutical generic medicine suppliers. To know more details about Nelarabine, dial the toll-free no. 18008891064.